Safety and efficacy of platelet-rich plasma in treatment of carpal tunnel syndrome; a randomized controlled trial

Table 2 The comparison of quantitative variables between control and treatment groups at the beginning of study

Variables	Group	Number	Mean	SD	P Value	Power
Age	Splint	20	47.23	7.11	0.06	0.419
Age	PRP+ Splint	21	51.20	9.82	0.06	0.419
Duration	Splint	20	14.13	8.55	0.09	0.064
Duration	PRP+ Splint	21	13.74	11.5	0.09	0.064
VAS	Splint	20	6.24	1.17	0.28	0.443
VAS	PRP+ Splint	21	6.82	1.24	0.28	0.443
Median SNAP PL	Splint	20	4.05	0.22	0.03	0.462
Median SNAP PL	PRP+ Splint	21	4.25	0.52	0.03	0.462
Median CMAP OL	Splint	20	4.06	0.55	0.24	0.107
Median CMAP OL	PRP+ Splint	21	4.13	0.53	0.24	0.107
SSS	Splint	20	2.73	0.40	0.58	0.475
SSS	PRP+ Splint	21	2.43	0.73	0.58	0.475
FS	Splint	20	2.54	0.62	0.16	0.349
FS	PRP+ Splint	21	2.36	0.83	0.16	0.349

ISSN: 1471-2474